Sonidegib

Products

Sonidegib was approved in many countries in 2015 in capsule form (Odomzo).

Structure and properties

Sonidegib (C₂₆H₂₆F₃N₃O₃, M_r = 485.5 g/mol) is present in the drug as sonidegib diphosphate. It is a biphenyl carboxamide.

Effects

Sonidegib (ATC L01XX48) has antitumor and antiproliferative properties. The effects are due to inhibition of the Hedgehog signaling pathway by binding to the membrane protein Smoothened, ultimately leading to decreased transcription of growth-promoting genes. Sonidegib has a long half-life of 28 days.

Indications

For the treatment of advanced basal cell carcinoma (2nd-line agent).

Dosage

According to the SmPC. Capsules are taken once daily on an empty stomach, at least one hour before or two hours after a meal. Administration is always at the same time of day.

Contraindications

• Pregnancy and lactation

For complete precautions, see the drug label.

Interactions

Sonidegib is metabolized primarily by CYP3A4 and corresponding drug-drug interactions are possible.

Adverse effects

The most common possible adverse effects include:

• Muscle cramps, muscle pain
• Hair loss
• Taste disorders
• Fatigue
• Nausea, diarrhea, weight loss, decreased appetite, abdominal pain, vomiting.
• Headache, pain
• Itching